present
We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass
- Conducted groundbreaking scientific discoveries, driving groundbreaking discoveries and breakthroughs in the field.
- Publishing groundbreaking research findings in top-tier scientific journals.
- Expanding operational efficiency and driving impactful growth through strategic planning and targeted marketing campaigns.
- Discovering new information about animals, revolutionizing their understanding, and developing new scientific solutions.
- Developing groundbreaking scientific discoveries and breakthrough discoveries with precision and expertise.
- Driving strategic initiatives to expand market presence and enhance patient outcomes in immunopharmacological research.